tbuckley/cabot-search huggingface dataset:
Regulation of pathways downstream of mTOR by imatinib mesylate in CML cells
Authors: O. Aranha, S. Kaur, J. Smith, A. Sassano, L. C. Platanias
Journal: Journal of Clinical Oncology (2006)

6595 Background: The differential regulation of signaling pathways downstream of the BCR-ABL tyrosine kinase are being defined in an effort to improve therapeutic strategies for patients with CML. We have previously shown that imatinib mesylate suppressed p70 S6 kinase activity, consistent with inhibition of BCR-ABL-mediated activation of the mTOR/p70 S6 kinase pathway. In this study we examined the effects of imatinib mesylate on other target proteins downstream of mTOR. Methods: BCR-ABL expressing cell lines (K562, KT1 and BV173) were treated with 1μM of imatinib mesylate for 30, 60 and 90 minutes, and then lysed in phosphorylation lysis buffer. Immunoblotting was done using standard enhanced chemiluminescence (ECL) methods. In the experiments in which the pharmacologic inhibitor of mTOR, rapamycin was used, the cells were pretreated for 60 minutes with the inhibitor and subsequently treated with imatinib. Results: The translational repressor 4E-BP1 is constitutively phosphorylated in CML cells. In the presence of imatinib mesylate in concentrations as low as 1μM, the phosphorylation of 4E-BP1 on threonine sites 37 and 46 is decreased. The phosphorylation of eIF-4G on serine site 1108 is also inhibited by imatinib mesylate treatment as early as 60 minutes. The combination of the mTOR inhibitor rapamycin and imatinib mesylate was more potent in suppressing phosphorylation of 4E-BP1 than imatinib alone, suggesting a mechanism for the enhancing effects of rapamycin on imatinib mesylate-dependent inhibition of growth of BCR-ABL cells. Conclusions: Our results further suggest the potential development of future clinical-translational studies utilizing rapamycin in combination with imatinib for the treatment of patients with CML. No significant financial relationships to disclose.
The Isocortex of Man
Authors: Percival Bailey, Gerhardt von Bonin
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Critical review of liability for benzodiazepine abuse among alcoholics
Authors: D A Ciraulo, B F Sands, R I Shader
Journal: American Journal of Psychiatry (1988)

The authors critically reviewed the literature on benzodiazepine use among alcoholics, psychiatric patients, and the general population to determine whether alcoholics have a greater liability for benzodiazepine abuse. Data suggest that the prevalence of benzodiazepine use among alcoholics is greater than in the general population but comparable to the prevalence in psychiatric patients. The liability for abuse may also be greater for alcoholics, but the substantial methodologic deficiencies of existing studies preclude such a conclusion. Given the frequency of anxiety disorders and benzodiazepine use among alcoholics, their potential for benzodiazepine abuse is an important issue. The authors discuss clinical guidelines and strategies for future research.
Targeted immunotherapy with gemtuzumab ozogamicin (GO) following reduced intensity allogeneic stem cell transplantation (RI AlloSCT) to reduce minimal residual disease (MRD) in children with acute myeloid leukemia (AML): MRD monitoring by Wilms tumor gene
Authors: E. Roman, M. Olszewski, M. Kletzel, M. Bhatia, B. Bradley, D. George, J. Garvin, P. Satwani, C. van de Ven, M. S. Cairo
Journal: Journal of Clinical Oncology (2007)

9532 Background: RI vs myeloablative (MA) AlloSCT in adults with AML is associated with significantly less transplant related mortality but increased rate of relapse, presumably secondary to MRD (Alyea et al; Blood, 2005). Quantification of the WT1 has been used successfully to detect MRD in children with acute myeloid leukemia (AML) (Kletzel et al; Pediatr Dev Pathol, 2002). GO has induced ORR in &gt;30% of patients with overt relapsed CD33 + AML and may have a better effect in the setting of MRD (Sievers et al; J Clin Oncol, 2001). We have shown that RI AlloSCT followed by 2 doses of GO in average risk AML has resulted in &gt;94% donor chimerism (Roman/Cairo, Clin Can Res, 2005). We explored changes in MRD prior to and after consolidation with 2 doses of GO targeted immunotherapy in children with average risk AML post RI AlloSCT. Methods: 11 pts, 11 years (0.5–21) with CD33 + (8 CR1, 3 CR2) received fludarabine 30 mg/m 2 x6d and busulfan 3.2–4 mg/kgx2d. Donors: 7 6/6 HLA related peripheral blood stem cells (RPBSC), 1 5/6 RPBSC, 1 6/6 related cord blood (CB) and 2 4/6 unrelated CB. GOx2 was administered =60d post AlloSCTx2 (8wks apart), at 4.5–7.5 mg/m 2 (dose escalation). Samples were collected for WT1 analysis prior to and after each dose of GO (n=5). WT1 levels were determined by quantitative RT-PCR and compared with WT1 expression in a K562 leukemia line. Positive MRD was a ratio of K562 WT/patient's WT1&gt;0.5. Results: The MTD for GO post RI AlloSCT has not been reached. 8/11 are NED (3 deaths: 1 relapse, 1 graft failure, 1 cGVHD) Pre GO WT1–0.079±0.07 (n=5), pre GO-dose #2–0.012±0.016 (n=3). One of these patients had detectable MRD (WT1–1.56) prior to the GO-dose #2, no MRD at 1year and is alive and in remission at 2 years post GOx2. The fifth patient entered transplant with +MRD (WT-0.866), relapsed after the first dose of GO and died of relapse prior to receiving the second dose. Conclusions: Targeted therapy with GOx2 may be useful in eradicating MRD in patients post RI AlloSCT. A larger cohort is necessary to assess the impact of GO (at the MTD) on MRD post RI AlloSCT in children with AML. No significant financial relationships to disclose.
In situ hybridization of carbon nanotubes with bacterial cellulose for three-dimensional hybrid bioscaffolds
Authors: Subeom Park, Jooyeon Park, Insu Jo, Sung-Pyo Cho, Dongchul Sung, Seungmi Ryu, Minsung Park, Kyung-Ah Min, Jangho Kim, Suklyun Hong, Byung Hee Hong, Byung-Soo Kim
Journal: Biomaterials (2015)
Abstract 359: Left Ventricular Strain and Strain Rate Imaging in Asymptomatic Patients With Type 2 Diabetes Mellitus
Authors: Arnold C Ng, Victoria Delgado, Rutger W van der Meer, Matteo Bertini, Gaetano Nucifora, Dominic Y Leung, Nico R van de Veire, Hildo J Lamb, Martin J Schalij, Jeroen J Bax
Journal: Circulation (2009)
Communicable disease control in a migrant seasonal workers population: A case study in Norway
Authors: P J Guérin, L Vold, P Aavitsland
Journal: Eurosurveillance (2005)

Reliable data on the health status of migrant seasonal workers in Europe is scarce. Access to public health care for this population depends on national regulations, and their legal status in host countries. In this manuscript we describe a case study of a salmonellosis outbreak that occurred in Norway, and highlight the difficulties encountered in applying control measures in a population of seasonal migrant farm workers. Surveillance and control of infectious diseases need to be supported by legislation which makes implementation of control measures possible. Efforts have been made to improve the rights for migrants in Europe with regard to healthcare, but seasonal migrant workers still remain largely outsiders where these measures are concerned. Special attention should be given to this disadvantaged group in terms of social rights and healthcare. Preparedness plans should be improved to deal with contagious pathogens involving the seasonal migrant population.
Pathology and Treatment of Diseases of the Skin, for Practitioners and Students.
Authors: Moriz Kaposi, James C. Johnston
Journal: JAMA (1895)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Sex Offenses: The Problem, Causes and Prevention
Authors: Manfred S. Guttmacher
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Nilotinib in chronic myelogenous leukemia patients who failed prior imatinib and dasatinib therapy: Updated results of an open-label phase II study
Authors: E. Abruzzese, G. Alimena, P. le Coutre, K. N. Bhalla, G. J. Ossenkoppele, A. Haque, N. Gallagher, H. M. Kantarjian, F. J. Giles
Journal: Journal of Clinical Oncology (2008)

7055 Background: Few therapeutic options exist for patients (pts) with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) who are resistant to or intolerant of both imatinib, the standard of care, and dasatinib. This open-label phase 2 study was designed to evaluate the safety and efficacy of nilotinib in such pts. Methods: Nilotinib was administered at a dose of 400 mg twice daily (BID) to pts with CML chronic phase (-CP), accelerated phase (-AP), or blast crisis (-BC) who were either resistant or intolerant to both imatinib and dasatinib therapy. Pts who had inadequate hematologic and/or cytogenetic responses at 28 days or who had disease progression could be escalated to 600 mg BID nilotinib in the absence of safety concerns. Results: A total of 78 evaluable pts were reported (CP, n = 34; AP, n = 18; BC, n = 26). Median duration of prior dasatinib use was 188 days. Primary reasons for dasatinib discontinuation were disease progression (51%) and adverse events (AEs) (41%). Median duration of nilotinib exposure was 112 (4- 632) days for all pts. A total of 27 (35%) pts with dasatinib failure remained on nilotinib at time of data cut-off and 51 (65%) discontinued treatment (12 for AEs, 29 for disease progression, 10 for other reasons). The outcome for CML-CP patients was the following: 18 (78%) of 23 pts with CML-CP who did not have a complete hematologic response (CHR) at baseline, achieved CHR; 8/29 (28%) CML-CP pts achieved a major cytogenetic response (MCyR) and 3/29 (10%) a complete CyR (CCyR) on nilotinib. Of 16 pts with CML-AP, 6 (38%) achieved a confirmed HR and 2 (13%) a MCyR on nilotinib therapy. Of 25 pts with CML-BC, 2 (8%) had evidence of HR and 3 (12%) had MCyR. For all pts (N = 78), the most common Grade 3/4 hematologic laboratory abnormalities reported were neutropenia (51%), thrombocytopenia (41%), anemia (22%), and hypophosphatemia (18%). Non-hematologic toxicities were mild overall and included rash, nausea, and diarrhea. Conclusions: Nilotinib demonstrates clinical activity in CML-CP, -AP, and -BC pts in whom both imatinib and dasatinib therapy have failed. Furthermore, nilotinib is generally well tolerated in this heavily pretreated pt population with limited treatment options. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Novartis Bristol-Myers Squibb, Novartis Bristol-Myers Squibb, Novartis Merck, Novartis
Radium and Other Radioactive Substances; Polonium, Actinium and Thorium, with a Consideration of Phosphorescent and Fluorescent Substances, the Properties and Applications of Selenium and the Treatment of Disease by the Ultra-violet Light.
Authors: William Joseph Hammer
Journal: JAMA (1904)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Enteroliths in a Kock continent ileostomy: case report and review of the literature
Authors: Hadi Moattar, Jakob Begun, Timothy Florin
Journal: Endoscopy (2015)

The Kock continent ileostomy (KCI) was designed by Nik Kock, who used an intussuscepted ileostomy loop to create a nipple valve ([Fig. 1]) that would not leak and would allow ileal effluent to be evacuated with a catheter [1]. Enterolith formation is a rarely reported long-term complication of KCI that can lead to disabling symptoms mandating treatment [2] [3] [4].
The Uniqueness of Man
Authors: E. James Potchen
Journal: JAMA (1970)

"The effort to understand the only being who has made an effort to understand will keep man occupied, one suspects, for a long time to come." Considerations of our very existence are amply put forth by the contributors to this discussion resulting from the Nobel conference at Gustavus Adolphus College in 1968. This book presents a series of papers all written by outstanding individuals and directed toward the uniqueness of man. Sir John Eccles discusses the philosophy of the person because "I wish to do all I can to restore to mankind the sense of wonder and mystery that arises from the attempt to face up to the reality of our very existence as conscious beings." W. H. Thorpe expresses the opinion that scientific advances of the future will come from "accepting the view that man's intellect acquires knowledge by a real act of personal faith, a readiness to believe
Celecoxib combined with fixed dose-rate gemcitabine (FDR-Gem)/CDDP as induction chemotherapy for stage III non-small cell lung cancer (NSCLC)
Authors: M. Milella, A. Ceribelli, A. Gelibter, P. Malaguti, B. Di Cocco, F. Cecere, F. Facciolo, V. Cerasoli, A. Mirri, F. Cognetti
Journal: Journal of Clinical Oncology (2005)

7324 Background: Induction chemotherapy with platinum-containing doublets followed by definitive loco-regional treatment is currently considered the treatment of choice for pts with stage III NSCLC. Based on evidence produced by our group that FDR-Gem results in a longer PFS when combined with CDDP in the metastatic setting (Ceribelli et al., Cancer 2003) and on recent studies suggesting that the addition of selective COX-2 inhibitors to CBDCA/Paclitaxel combinations may improve results in the neoadjuvant setting (Altorki et al., JCO 2003), we have elected to investigate the activity of Celecoxib combined with FDR-Gem/DDP as induction treatment for locally advanced NSCLC pts. Methods: Treatment consisted of continuous Celecoxib (400 mg b.i.d.) combined with FDR-Gem (1200 mg/m2 infused at 10 mg/m2/min on days 1 and 8) and CDDP (80 mg/m2 on day 1) given q3 wks for three cycles. Upon restaging, non-progressive pts underwent surgery and/or definitive RT, as evaluated by a multidisciplinary team. Results: 19 pts (median age 59 yrs, range 43–68; M/F 14/5; IIIA/IIIB: 13/6; PS 0/1: 17/2) have been accrued to date and are evaluable for response and toxicity. Three pts (16%) achieved a cCR, 7 (37%) a PR, 7 (37%) had SD, and 2 (10%) progressed on therapy. Nine pts underwent radical surgery, of whom 2 showed a pCR with no evidence of viable tumor cells in the resected specimen; 5 pts underwent RT with curative intent, 1 of whom became resectable and underwent radical surgery after RT. Toxicity was manageable with G3 neutropenia and anemia in 6/19 and 5/19 pts, respectively, and only 1 pt experiencing G3 vomiting. Treatment delays/25% dose reductions were necessary in 14/114 and 9/114 administrations, respectively. One pt discontinued Celecoxib due to G2 erosive duodenitis. With a median follow-up of 42 wks (range 13–74), 9 pts are alive and free from progression. Conclusions: Celecoxib combined with FDR-Gem/CDDP shows promising activity in locally advanced NSCLC and warrants further investigation in the neoadjuvant setting. Accrual is ongoing to reach a planned target of 42 evaluable patients. No significant financial relationships to disclose.
Hungarian insurance companies raise malpractice premiums
Authors: Carl Kovac
Journal: BMJ (1999)

In the wake of an increase in the number of malpractice lawsuits and in the size of their claims, Hungarian insurance companies are increasing the premiums on contracts, and one of the country's leading companies is removing its coverage from 92 hospitals.

Hungarian law stipulates that all healthcare facilities must insure their doctors against malpractice claims. Fees range from a few hundred thousand to several …
Controversies: Is it time to stop searching for MRSA? (Stop the ritual of tracing colonised people)
Authors: E L Teare, S P Barrett
Journal: BMJ (1997)

Health care increasingly emphasises the team approach in which doctors, nurses, and other health workers adapt and develop new skills.Before changes of this kind are widely accepted, however, there must be clarity about the training, status, authority, working relationships, career structure, and remuneration of those who undertake responsibilities well beyond their traditional roles.
Value of Blood Grouping in Anthropology.
Authors: 種基 古畑
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
L'Hématoblaste Troisième Élément du Sang.
Authors: G. Hayem, Lucien Rivet
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Werner's The Thyroid: A Fundamental and Clinical Text.
Authors: Sidney H Ingbar, Lewis E Braverman
Journal: Annals of Internal Medicine (1988)

versial is the notion that it may be safe to lower the pressure abruptly to normal levels, a strat- egy that.can lead to cerebral and optic nerve ischemia.On balance the misinforma- tion in this book outweighs the information.